ST-101 / Stratus Therapeutics - LARVOL DELTA

Generation of HLA-Compatible Hematopoietic Stem Cells from iPSCs Using a GMP-Compliant Platform for Transplantation Applications (TCT-ASTCT-CIBMTR 2026) - "The Stratus Prime™ platform enables GMP manufacturing of HLA-edited HSPCs from iPSCs, offering an off-the-shelf, donor-independent solution for hematopoietic stem cell transplantation. The ST-101 product shows high engraftment potential, lacks T cells to avoid GvHD, and is HLA-edited to match a large segment of the population. These data support advancement into first-in-human clinical trials."

First-in-human • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation • CD34 • HLA-DPB1 • HLA-DQB1

ST-101: Manufacturing GMP-compliant HLA-compatible definitive human hematopoietic stem and progenitors cells from iPSCs using Piezo1 agonists for clinical transplant (ASH 2025) - "The strong pre-clinical safety and efficacy data provides support foradvancing ST-101 into human clinical trials.1 Scapin, et al. American Journal of Hematology 100.6 (2025): 963-979."

Clinical • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Transplant Rejection • Transplantation • CD34 • HLA-DPB1 • HLA-DQB1